Adverum Biotechnologies, Inc. (ADVM:NASDAQ) closed at $4.36 on December 9, 2025, unchanged on the day. The stock trades 24.2% below its 52-week high of $5.75 and 144.9% above its 52-week low of $1.78. Adverum Biotechnologies, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 14, 2025, ADVM closed higher on 16 days (6%). Its best day was October 14, 2025 (+10.34%) and its worst was October 17, 2025 (-5.92%). The stock moved 10% or more in a single session 1 time.
Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.
Find more stocks like ADVM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.